Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2015.01.011 | DOI Listing |
J Am Acad Dermatol
April 2015
Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy. Electronic address:
PLoS One
September 2013
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Purpose: Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!